{"nctId":"NCT00424190","briefTitle":"Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections","startDateStruct":{"date":"2007-02"},"conditions":["Bacterial Infections"],"count":698,"armGroups":[{"label":"Ceftaroline for Injection","type":"EXPERIMENTAL","interventionNames":["Drug: Ceftaroline"]},{"label":"IV Vancomycin and IV Aztreonam","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: IV Vancomycin plus IV Aztreonam"]}],"interventions":[{"name":"IV Vancomycin plus IV Aztreonam","otherNames":["Active Comparator"]},{"name":"Ceftaroline","otherNames":["Experimental"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Skin and skin structure infection (SSSI) that involves deeper soft tissue or requires significant surgical intervention, or cellulitis or abscess on lower extremity which occurs in subjects with diabetes mellitus or well-documented peripheral vascular disease.\n\nExclusion Criteria:\n\n* Prior treatment of current cSSSI with an antimicrobial.\n* Failure of vancomycin or aztreonam as therapy for the current cSSSI, or prior isolation of an organism with in vitro resistance to vancomycin or aztreonam.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Clinical Cure Rate at Test of Cure (TOC) (MITT Population)","description":"Cure: Total resolution of all signs and symptoms of the baseline infection, or improvement of the infection such that no further antimicrobial therapy was necessary.\n\nFailure: Requirement of alternative antimicrobial therapy for primary infection of cSSSI due to inadequate response, recurrence, new infection at the same site; treatment-limiting adverse event (AE); requirement for surgery due to failure of study drug; diagnosis of osteomyelitis after Study Day 8; or death caused by cSSSI.\n\nIndeterminate: Inability to determine an outcome","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"304","spread":null},{"groupId":"OG001","value":"297","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]}]},{"type":"PRIMARY","title":"Clinical Cure Rate of Ceftaroline Compared With That of Vancomycin Plus Aztreonam Treatment at TOC in the Clinically Evaluable (CE) Population","description":null,"classes":[]},{"type":"SECONDARY","title":"Microbiological Success Rate at the TOC Visit","description":null,"classes":[]},{"type":"SECONDARY","title":"Clinical Response at the End of Therapy (EOT) Visit","description":null,"classes":[]},{"type":"SECONDARY","title":"Clinical and Microbiological Response by Pathogen at the TOC Visit","description":null,"classes":[]},{"type":"SECONDARY","title":"Clinical Relapse at the Late Follow Up (LFU) Visit","description":null,"classes":[]},{"type":"SECONDARY","title":"Microbiological Reinfection or Recurrence at the LFU Visit","description":null,"classes":[]},{"type":"SECONDARY","title":"Assess Safety","description":"Comparisons of the number of participants with Adverse Events","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":16,"n":351},"commonTop":["Pruritus","Nausea","Headache","Pruritus generalized","Diarrhea"]}}}